Senses Disorder TRIZ Cases

Temperature-induced phase transition extends drug residence time on the ocular surface while maintaining liquid administration ease.

Ocular insert resists deflection in the conjunctival sac, maintaining sustained drug release while preventing displacement and vision interference.

siRNA-mediated mTOR inhibition reduces lesion size and activates autophagy, addressing incomplete VEGF blockade in macular degeneration.

Lipophilic hyaluronic acid stabilizes collagenase to remove necrotic tissue while protecting healthy tissue.

MANF and CDNF neurotrophic factors preserve outer nuclear layer thickness and rescue retinal ganglion cells to halt progressive vision loss.

Deuterium-enriched thiazolidinediones resist racemization at the chiral center through stronger carbon-deuterium bonds.

Composite hydrogel and alginate particles absorb excess exudate while maintaining a moist healing environment.

Optimized AAV vectors expressing Nrf2 via specific promoters reduce retinal toxicity while maintaining therapeutic efficacy.

AKP-001 p38 MAP kinase inhibitor suppresses TGF-beta signaling to treat Fuchs dystrophy without corneal transplantation.

Synthetic cell-penetrating peptides deliver CRISPR components safely, bypassing viral vector toxicity while maintaining high cellular uptake efficiency.

Polymeric vehicles like hyaluronic acid or PLGA deliver anti-neovascular agents intravitreally, preventing dry AMD progression while minimizing systemic toxicity.

Near-infrared light activates heptamethine dyes to generate singlet oxygen and induce scleral crosslinking.

Gene therapy delivering soluble membrane-independent CD59 reduces MAC deposition and protects ocular tissues from complement-mediated damage in AMD.

Cyclic indolizinecarboxamides inhibit renin, replacing complex peptidic structures with simplified non-peptidic cores to improve oral bioavailability.

Bioerodible implants release dexamethasone through PLGA hydrolysis, reducing injection frequency and systemic side effects for ocular conditions.

SPARC binding single chain variable fragments couple to therapeutic agents, increasing concentration at tumor sites.

Engineered anion channel rhodopsins accelerate chloride conduction kinetics and lower light intensity requirements for precise neuronal silencing.

A release mechanism uses a non-linear force profile to provide tactile feedback during injection device operation.

Cyclohexane derivatives modulate the PGI2 receptor to enable stable oral prostacyclin analogs.

Administering phentolamine at bedtime minimizes eye redness during waking hours while maintaining sustained visual performance improvements.

Engineered rAAV2.7m8 viral vectors deliver anti-VEGF transgenes to ocular tissues, eliminating frequent injection requirements.

A water-soluble pharmaceutical composition utilizes methyl-beta-cyclodextrin to encapsulate hydrophobic N-acyl-ethanolamines.

Pyridinyl derivatives inhibit AOC3 while minimizing AOC1 binding to reduce adverse side effects.

Pyrazole-pyrimidine carboxamide compounds inhibit JAK kinases to treat autoimmune diseases while reducing toxic side effects.

Synthesizing CFTR modulators via amide coupling addresses defective protein folding and trafficking in cystic fibrosis.

Bupleurum extract inhibits TNF-alpha and IL-6 to treat rheumatoid arthritis without expensive biologics.

Combining phage display with next-generation sequencing to globally identify and quantify biological ligands.

Simultaneous blockade of IP and EP4 receptors reduces neovascularization area, overcoming insufficient inhibition from single-agent therapies.

Tritoqualine combines CFTR modulation with NK1 receptor inhibition to treat dry eye syndrome by addressing both aqueous-deficient and evaporative forms.

Thymosin beta 4 compositions accelerate corneal re-epithelialization to resolve the trade-off between reducing inflammation and healing rate.

Proline analog compounds resolve specificity and efficacy trade-offs by targeting CB1 and CB2 receptors with tailored substituent patterns.

Pyrrolo-pyridine compounds inhibit tyrosine kinase activity to treat proliferative diseases.

Diamino-pyridine compounds modulate histamine H4 receptors to inhibit leukocyte recruitment and reduce inflammatory mediators.

Segmenting chemical structures into distinct carbamate series expands therapeutic options beyond insufficient existing inhibitors.

Substituted azoanthracene derivatives activate the GLP-1 receptor, replacing unstable peptides to overcome rapid proteolysis and improve glycemic control.

A dual hybrid AAV vector system segments large genes into two sequences to facilitate recombination in target cells.

AICAR activates AMP kinase to suppress leukocyte infiltration and NF-kB activity, avoiding adverse effects from corticosteroids.

Segmenting alkyl chain lengths reduces ocular toxicity while maintaining preservative efficacy and emulsion stability.

Pyrroloquinoline quinone and sulfonic acid vitamin D treat Sjogren's syndrome by inhibiting oxidative stress.

A 4,4-disubstituted cyclohexyl bridge in heptamethine cyanine dyes reduces over-quenching while maintaining high sensitivity for in vivo imaging.

Synthetic PIF peptide analogs delay visual function decline and preserve photoreceptor cells, addressing the lack of effective treatments for genetic blindness.

6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine compounds inhibit PDE4B isoform enzymes with high binding affinity.

Phosphonate surrogates resolve solubility contradictions in sphingosine 1-phosphate analogs, enabling potent S1P1 receptor modulation for autoimmune therapies.

Modular depth filtration, affinity capture, and anion-exchange steps separate full from empty rAAV particles while reducing residual DNA contamination.